NCT Number: NCT02194270
Relative Bioavailability of Ambroxol Hydrochloride of Soft Pastilles Compared to Ambroxol Hydrochloride Syrup in Healthy Male and Female Volunteers
Study to investigate the relative bioavailability of ambroxol hydrochloride soft pastilles 15 mg vs. ambroxol hydrochloride (HCL) 15 mg of syrup (15mg/5mL, Reference I) and ambroxol hydrochloride 15 mg of syrup (30mg/5mL, Reference II) in a fasted state
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–55 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy males and females according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead Electrocardiogram (ECG), clinical laboratory tests
- No finding deviating from normal and of clinical relevance
- No evidence of a clinically relevant concomitant disease
- Age ≥18 and Age ≤55 years
- BMI ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index)
- Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation
Exclusion criteria
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- History of relevant orthostatic hypotension, fainting spells or blackouts
- Chronic or relevant acute infections
- History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
- Participation in another trial with an investigational drug within two months prior to administration or during the trial
- Smoker (more than 10 cigarettes or 3 cigars or 3 pipes/day)
- Alcohol abuse (more than 60 g/day)
- Drug abuse
- Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- Excessive physical activities (within one week prior to administration or during the trial)
- Any laboratory value outside the reference range that is of clinical relevance
- Inability to comply with dietary regimen of study centre
For female subjects:
- Pregnancy
- Positive pregnancy test
- No adequate contraception e.g. oral contraceptives, sterilization, intrauterine device (IUD)
- Inability to maintain this adequate contraception during the whole study period
- Lactation period
Treatment and study plan
Ambroxol hydrochloride - syrup - low dose
DrugAmbroxol hydrochloride - syrup - high dose
DrugPrimary outcomes
-
AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)
Time frame: up to 30 hours after each drug administration
-
Cmax (maximum concentration of the analyte in plasma)
Time frame: up to 30 hours after each drug administration
Secondary outcomes
-
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)
Time frame: up to 30 hours after each drug administration
-
tmax (time from dosing to the maximum concentration of the analyte in plasma)
Time frame: up to 30 hours after each drug administration
-
λz (terminal rate constant in plasma)
Time frame: up to 30 hours after each drug administration
-
t1/2 (terminal half-life of the analyte in plasma)
Time frame: up to 30 hours after each drug administration
-
MRTpo (mean residence time of the analyte in the body after p.o. (oral) administration)
Time frame: up to 30 hours after each drug administration
-
CL/F (apparent clearance of the analyte in the plasma after extravascular administration)
Time frame: up to 30 hours after each drug administration
-
Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)
Time frame: up to 30 hours after each drug administration
-
Number of patients with adverse events
Time frame: up to 40 days
-
Number of patients with abnormal changes in laboratory parameters
Time frame: up to 40 days
-
Number of patients with clinically significant changes in vital signs (BP (Blood pressure), PR (Pulse rate))
Time frame: up to 40 days
-
Assessment of tolerability by investigator on a 4-point scale
Time frame: within 8 days after last administration
Sponsors and collaborators
Lead sponsor
Boehringer Ingelheim
Industry
Registry information
Official study title
Relative Bioavailability of Ambroxol Hydrochloride Following Oral Administration of Soft Pastilles 15 mg (Test) Compared to 15 mg of Syrup (15mg/5mL, Reference I) and Compared to 15 mg of Syrup (30mg/5mL) (Reference II) in Healthy Male and Female Volunteers. An Open-label, Randomised, Single-dose, 3-way Crossover Study
Important dates
- Study start
- 2004
- Primary completion
- 2005
- First posted
- Jul 18, 2014
- Registry last updated
- Jul 18, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Characterization of Gastric Evoked Potentials
NCT05924009
Healthy
Pittsburgh, Pennsylvania, United States
View Trial DetailsTo Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers
NCT07374406
Healthy
Jeonju, South Korea
View Trial DetailsDimensional Changes of the Keratinized Mucosa in Edentulous Ridges Following Accordian Technique Versus Conventional Free Gingival Grafts
NCT07365865
Deficient Keratinized Mucosa, Healthy
Cairo, Egypt
View Trial DetailsValidation of a Digital Twin Performing Strength Training
NCT04849923
Healthy
Winterthur, Canton of Zurich, Switzerland
View Trial Details